TEN PERCENT (10%) JUNIOR SECURED COLLATERALIZED CONVERTIBLE PROMISSORY NOTE Due Deferral end dateXenetic Biosciences, Inc. • July 8th, 2016 • Pharmaceutical preparations • New York
THIS TEN PERCENT (10%) JUNIOR SECURED COLLATERALIZED CONVERTIBLE PROMISSORY NOTE is a duly authorized and validly issued Ten Percent (10%) Junior Secured Collateralized Convertible Promissory Note of Xenetic Biosciences, Inc., a Nevada corporation (the “Company” or the “Borrower”), having its principal place of business at 99 Hayden Ave, Suite 230, Lexington, Massachusetts 02421, designated as its Ten Percent (10%) Junior Secured Collateralized Convertible Promissory Note due on the Deferral End Date (the “Note”).
COMMON STOCK PURCHASE WARRANT XENETIC BIOSCIENCES, INC.Xenetic Biosciences, Inc. • July 8th, 2016 • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, M. Scott Maguire (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the earlier to occur of July 1, 2016 or the Measurement Date (as that term is defined in that certain Asset Purchase Agreement, dated as of November 13, 2015, as amended, among AS Kevelt, PJSC Pharmsynthez (f/k/a OJSC Pharmsynthez), the Company and Lipoxen Technologies, Ltd.)(the “Initial Exercise Date”) and on or prior to the close of business on the five (5) year anniversary of the Issue Date written above (the “Termination Date”) but not thereafter, to subscribe for and purchase from Xenetic Biosciences, Inc., a Nevada corporation (the “Company”), up to 37,369 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Ex
DEFERRED SALARY SECURITY AGREEMENTDeferred Salary Security Agreement • July 8th, 2016 • Xenetic Biosciences, Inc. • Pharmaceutical preparations • Nevada
THIS DEFERRED SALARY SECURITY AGREEMENT dated as of July 1, 2016 is by and between Xenetic Biosciences, Inc. (“Xenetic”) and M. Scott Maguire (“MSM”).
